Business
Ilika Secures Stereax Electrode Order from Cirtec
Ilika plc has secured its first revenue-generating purchase order from Cirtec Medical for Stereax electrodes, marking a commercial transition in their strategic partnership. This order follows two years of development and successful prototype delivery, supporting Cirtec's ramp-up of Stereax M300 production for active implantable medical devices. This signifies Ilika's entry into the commercial phase for its medical device battery technology, with 21 customers currently evaluating the Stereax M300 batteries. Disclaimer*
About this update from Ilika Plc
[{"type":"text","content":"\n\n21 January 2026\nIlika plc\n('Ilika,' the 'Company,' or the 'Group')\n \nIlika Secures First Stereax Electrode Order from Cirtec\n \nStrategic Partnership Advances to Revenue Generation Phase\n \nIlika (AIM: IKA), the UK pioneer in solid state battery technology, has secured its first revenue-generating purchase order from Cirtec Medical (Cirtec) for the supply of Stereax electrodes, marking the commercial transition of this strategic partnership. This milestone order for the critical conductive elements that enable battery functionality follows two years of development work and successful prototype delivery in December 2025.\n \nThe Stereax electrodes will support the ramp up of Stereax M300 production at Cirtec, targeting a wide range of applications across active implantable medical devices (AIMDs), including powering implanted sensors, neurostimulators, orthopaedic implants, orthodontic wearables and ophthalmology devices. This purchase represents Ilika's entry into the commercial phase of its medical device battery technology.\n \nIn August 2023, Ilika announced an agreement whereby the Company would retain specific battery manufacturing processes at its UK facility as a service to Cirtec. After successfully delivering early versions of Stereax M300 batteries in December 2025 (with primary manufacturing occurring at Cirtec's Massachusetts facility), this relationship has now progressed to commercial orders, with Cirtec purchasing production quantities of electrodes from Ilika. The Stereax M300 batteries are currently being evaluated by 21 customers for their applications.\n \nShawn Martin, Vice President at Cirtec Medical, said: \"This marks an important transition from the earlier stages of technology transfer to commercial production coordinated from our facility here in the USA.\"\n \nGraeme Purdy, CEO of Ilika, said: \"The receipt of this first commercial electrode order validates the strong market momentum building behind our Stereax technology and demonstrates the successful execution of our production strategy. This revenue-generating phase of our partnership with Cirtec positions us to support their manufacturing scale-up while accelerating product integration across numerous high-value medical device applications.\"\n \nThe companies will showcase their partnership at upc...